



Mario Bargetzi

Contact

Mario Bargetzi

Publications (20)

Brune M, Cogliatti S, Ossenkoppele G, Löwenberg B, Rudolf C, Li Q, Passweg J, Mazzuchelli L, Medinger M, Tzankov A, Fehr M, Grobholz R, Stussi G, Lundberg P, Vela V, Heim D, Manz M, Haralambieva E, Pabst T, Banz Y, Bargetzi M, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK). Effects of lenalidomide on the bone marrow microenvironment in acute myeloid leukemia: Translational analysis of the HOVON103 AML/SAKK30/10 Swiss trial cohort. *Ann Hematol* 2021; 100:1169-1179.

Ossenkoppele G, Pabst T, Oosterveld M, Obbergh F, Nijziel M, Moors I, Kooy M, Maertens J, Loosdrecht A, Legdeur M, Poel M, Sinnige H, Spertini O, Norden Y, Stussi G, Westerweel P, Weerdt O, Vellenga E, Vekemans M, Velden W, Tick L, Terpstra W, Lammeren-Venema D, Kuball J, Deeren D, Chalandon Y, Brouwer R, Breems D, Borne P, Biemond B, Bargetzi M, Manz M, Löwenberg B, Efthymiou A, Gjertsen B, Graux C, Klift M, Klein S, Jongen-Lavrencic M, Jie A, Jaspers A, Hoogendoorn M, Hess U, Heim D, Gregor M, Janssen J. Inferior Outcome of Addition of the Amino-peptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS. *Cancers (Basel)* 2021; 13

Ossenkoppele G, Porkka K, Cornelissen J, Kuball J, Fischer T, Legdeur M, Hoogendoorn M, Breems D, Moors I, van Lammeren-Venema D, Silzle T, Juliusson G, Meyer P, Floisand Y, Manz M, van Elssen C, Valk P, Cloos J, Passweg J, Huls G, Janssen J, Gjertsen B, Höglund M, Gregor M, Veelken H, van Marwijk Kooy M, Jongen-Lavrencic M, Tick L, Griskevicius L, Vellenga E, Spertini O, Biemond B, Gradowska P, Maertens J, Pabst T, Vekemans M, van der Velden W, Westerweel P, Gadisseur A, Klein S, Bargetzi M, van Esser J, de Weerdt O, Deeren D, Graux C, Michaux L, Beverloo B, Löwenberg B. Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial. *Blood Adv* 2021; 5:1110-1121.

Benz R, O'Meara Stern A, Cantoni N, Bargetzi M, Bianchi-Papina E, Rossi D, Passweg J, Lohri A, Berardi S, Feller A, Rauch D, Blum S, Mey U, Arn K, Andres M, Pabst T, Baumann M, Novak U, Hitz F, Hess U, Zenhausem R, Chalandon Y, Stussi G. Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial. *Blood Adv* 2020; 4:3699-3707.

Zucca E, Zander T, Bersvendsen H, Bargetzi M, Mingrone W, Krasniqi F, Dirnhofer S, Hayoz S, Hawle H, Vilei S, Ghielmini M, Kimby E, Novak U, Lohri A, Ferreri A, Rondeau S, Vanazzi A, Østenstad B, Mey U, Rauch D, Wahlin B, Hitz F, Hernberg M, Johansson A, de Nully Brown P, Hagberg H, Swiss Group for Clinical Cancer Research and the Nordic Lymphoma Group. Short regimen of rituximab plus lenalidomide in follicular lymphoma patients in need of first-line therapy. *Blood* 2019; 134:353-362.

Samaras P, Zander T, Taverna C, Schmidt A, Pabst T, Mey U, Matthes T, Lerch E, Ketterer N, Heim D, Duchosal M, Driessen C, Betticher D, Bargetzi M, Renner C. Updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. *Swiss Med Wkly* 2019; 149:w20031.

Ghilardi G, Ghielmini M, Wannesson L, Lerch E, Samaras P, Schanz U, Passweg J, Stussi G, Kleber M, Gerber B, Rossi D, Schmidt A, Pabst T, Jeker B, Müller R, Cairoli A, Müller A, Bargetzi M, Hitz F, Baldomero H, Heim D, Swiss Blood Stem Cell Transplantation Registry. Melphalan dose in myeloma patients >65 years of age undergoing high-dose therapy and autologous stem cell transplantation: a multicentric observational registry study. *Bone Marrow Transplant* 2018

Passweg J, Masouridi-Levrat S, Müller A, Nair G, Pabst T, Renner C, Schmidt A, Stussi G, Nicoloso de Faveri G, Schanz U, Leibundgut K, Hess U, Heim D, Baldomero H, Ansari M, Baerlocher G, Bargetzi M, Chalandon Y, Duchosal M, Gerull S, Güngör T, Halter J, For The Swiss Blood Stem Cell Transplantation Group Sbst. Haematopoietic cell transplantation in Switzerland, changes and results over 20 years: a report from the Swiss Blood Stem Cell Transplantation Working Group for Blood and Marrow Transplantation registry 1997-2016. *Swiss Med Wkly* 2018; 148:w14589.

Schnegg-Kaufmann A, Bonadies N, Arndt V, Stussi G, Passweg J, Chalandon Y, Spertini O, Hess U, Bargetzi M, Efthymiou A, Gregor M, Manz M, Rovó A, Baldomero H, Feller A, NICER Working Group. Improvement of relative survival in elderly patients with acute myeloid leukaemia emerging from population-based cancer registries in Switzerland between 2001 and 2013. *Cancer Epidemiol* 2017; 52:55–62.

Mey U, Ruefer A, Ziske C, Knauf W, Cathomas R, von Moos R, Hitz F, Sauter R, Hiendlmeyer E, Cantoni N, Bargetzi M, Fischer N, Doerfel S, Brugger W, Schwarb H, Pederiva S, Schwarzer A, Dechow T, Jehner P, Rauh J, Taverna C, Schmid M, Schmidt-Hieber M, Driessen C. Bendamustine, lenalidomide and dexamethasone (BRd) has high activity as 2(nd) -line therapy for relapsed and refractory multiple myeloma – a phase II trial. *Br J Haematol* 2016

Baumgartner A, Mueller B, Stanga Z, Hess U, Duchosal M, Pabst T, Wannesson L, Limonta A, Pichard C, Chalandon Y, Samaras P, Schanz U, Passweg J, Medinger M, Zueger N, Bargetzi A, Bargetzi M, Schuetz P. Nutritional support practices in hematopoietic stem cell transplantation centers: A nationwide comparison. *Nutrition* 2016; 35:43–50.

Mamot C, Zucca E, Dirnhofer S, Rusterholz C, Biaggi C, Samarin A, Hany T, Gigli F, Krasniqi F, Bargetzi M, Pless M, Mey U, Driessen C, Pabst T, Renner C, Hitz F, Klingbiel D, Martinelli G. Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). *J Clin Oncol* 2015; 33:2523–9.

Samaras P, Zander T, Taverna C, Pabst T, Mey U, Matthes T, Lerch E, Ketterer N, Hess U, Heim D, Duchosal M, Betticher D, Bargetzi M, Renner C. Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. *Swiss Med Wkly* 2015; 145:w14100.

Hitz F, Bargetzi M, Cogliatti S, Lohri A, Taverna C, Renner C, Mey U. Diagnosis and treatment of mantle cell lymphoma. *Swiss Med Wkly* 2013; 143:w13868.

Terwijn M, Graux C, Bargetzi M, Legdeur M, Kuball J, de Weerd O, Chalandon Y, Hess U, Verdonck L, Gratama J, Oussoren Y, Scholten W, Slomp J, Snel A, Vekemans M, Löwenberg B, Ossenkoppele G, Wijermans P, van Gelder M, van Putten W, Kelder A, van der Velden V, Brooimans R, Pabst T, Maertens J, Boeckx N, de Greef G, Valk P, Preijers F, Huijgens P, Dräger A, Schanz U, Jongen-Lavrecic M, Biemond B, Passweg J, Schuurhuis G. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study. *J Clin Oncol* 2013; 31:3889–97.

Passweg J, Schanz U, Stussi G, Stern M, Renner C, Pabst T, Ozsahin H, de Faveri G, Leibundgut K, Hess U, Güngör T, Gratwohl A, Duchosal M, Chalandon Y, Bucher C, Bargetzi M, Baldomero H, SBST (Swiss Blood Stem Cell Transplantation Group). Haematopoietic stem cell transplantation: activity in Switzerland compared with surrounding European countries. *Swiss Med Wkly* 2013; 143:w13757.

Wannesson L, Samaras P, Renner C, Pabst T, Lerch E, Hess U, Heim D, Cerutti A, Cairoli A, Bargetzi M, Zucca E. Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone). *Leuk Lymphoma* 2012; 54:36–40.

Renner C, Lohri A, Gyan E, Biaggi C, Cogliatti S, Bertoni F, Ghielmini M, Brauchli P, Ketterer N, Bouabdallah K, Trojan A, Zinzani P, Gressin R, Klingbiel D, Dietrich P, Hitz F, Bargetzi M, Mingrone W, Martinelli G, Swiss SAKK and French GOELAMS group from European Mantle Cell Lymphoma Network. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. *Haematologica* 2012; 97:1085–91.

Ghielmini M, Cerny T, Bargetzi M, Ketterer N, Stahel R, Pichert G, Schefer H, Betticher D, Fey M, Waltzer U, Bertoni F, Cogliatti S, Schmitz S, Swiss Group for Clinical Cancer Research. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2005; 23:705–11.

Ghielmini M, Vorobiof D, Bargetzi M, Lohri A, Helg C, Kovacsovics T, Stupp R, Zucca E, Hess U, Peccatori F, Martinelli G, Betticher D, Fey M, Waltzer U, Hummerjohann J, Pichert G, Cogliatti S, Schmitz S, Cerny T. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule. *Blood* 2004; 103:4416-23.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch